• IPSS parameters [ Time Frame: 4 and 8 weeks of treatment. ] [ Designated as safety issue: No ]
• BFLUTS-SF parameters [ Time Frame: 4 and 8 weeks of treatment ] [ Designated as safety issue: No ]
• Uroflowmetry & PVR parameters [ Time Frame: 4 and 8 weeks of treatment ] [ Designated as safety issue: No ]
• Micturition diary parameters [ Time Frame: 4 and 8 weeks of treatment ] [ Designated as safety issue: No ]
• Quality of life parameters [ Time Frame: 4 and 8 weeks of treatment ] [ Designated as safety issue: No ]
• Patient Perception of Bladder Condition [ Time Frame: 8 weeks of treatment ] [ Designated as safety issue: No ]
• Benefit, Satisfaction, and Willingness to Continue (BSW) Questions [ Time Frame: 8 weeks of treatment ] [ Designated as safety issue: No ]

The purpose of this study is to explore the efficacy of Alfuzosin (10 mg, qd) in reducing the score of International Prostate Symptom Score (IPSS) from baseline to 8 weeks of treatment in female patients with voiding dysfunction.

Trial design

Phase II, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the clinical efficacy and safety of alfuzosin (10mg, qd) from baseline to 8 weeks of treatment in female patients with non-neurogenic voiding dysfunction.

Efficacy Assessment

1. Primary efficacy endpoint

   Actual change in the score of IPSS from baseline to 8 weeks of treatment.

2. Secondary efficacy endpoint

   • IPSS parameters
   • Percent change in the score of IPSS from baseline to 4 and 8 weeks of treatment.
   • Actual and percent changes in the sub-scale of IPSS from baseline to 4 and 8 weeks of treatment
   • Storage score: sum of questions 2, 4 and 7
   • Voiding score: sum of questions 1, 3, 5 and 6
   • Scored form of the Bristol Female Lower Urinary Tract Symptoms (BFLUTS-SF)parameters
   • Actual and Percent change in BFLUTS-SF from baseline to 4 and 8 weeks of treatment.

   • Actual and percent changes in the sub-scale of BFLUTS-SF from baseline to 4 and 8 weeks of treatment

     • BFLUTS-FS: sum scores F1-F4
     • BFLUTS-VS: sum scores V1-V3
     • BFLUTS-IS: sum scores I1-I5
     • BFLUTS-sex: sum scores S1 & S2

   • Uroflowmetry & PVR parameters

     • Numeric and percent changes from baseline to 4 and 8 weeks of treatment.
     • Maximum flow rate (mL/s)
     • Average flow rate (mL/s)
     • Post-void residual urine (mL)
     • Micturition diary parameters
     • Change in mean number of micturitions per 24 hours at weeks 4 and 8 relative to baseline
     • Percent change of micturitions per 24 hours at weeks 4 and 8 relative to baseline
     • Change in mean number of nighttime micturitions per 24 hours at weeks 4 and 8 relative to baseline
     • Percent change of nighttime micturitions per 24 hours at weeks 4 and 8 relative to baseline
     • Change in mean number of urgency episodes per 24 hours at weeks 4 and 8 relative to baseline (Urgency episodes are defined as those with Bladder Sensation Scale rating of ≥ 3 in the diary).
     • Percent change of urgency episodes per 24 hours at weeks 4 and 8 relative to baseline
     • Change in the mean and sum rating on the Bladder Sensation Scale at weeks 4 and 8 relative to baseline
     • Quality of life (QoL) parameters
     • Change in Bother score of IPSS from baseline to 4 and 8 weeks of treatment.
     • Change in QOL subscale scores of BFLUTS SF from baseline to 4 and 8 weeks of treatment
     • BFLUTS-QoL: Sum scores QoL1-QoL5
     • Patient Perception of Bladder Condition (PPBC)
     • Change from baseline in PPBC after 8 weeks of double-blind treatment
     • Benefit, Satisfaction, and Willingness to Continue (BSW) Questions
     • Patient Perception of Treatment Benefit at week 8
     • Patient Perception of Treatment Satisfaction at week 8
     • Willingness to continue with treatment at week 8

• Drug: alfuzosin hydrochloride XL 10mg
• Drug: Placebo

• Experimental: alfuzosin hydrochloride XL 10mg
• Placebo Comparator: Placebo

Inclusion Criteria:

• Female aged ≥ 18
• Have voiding symptoms as chief complaints over 3 months
• IPSS symptom score ≥ 15
• A peak flow rate <12 mL/sec with a minimum voided volume of 100 mL and/or a postvoid residual urine volume >150 mL
• Underwent pressure-flow study

Exclusion Criteria:

• Patients who meet any of the following criteria are to be excluded from the study:
• Neurogenic voiding dysfunction
• Anatomic causes of bladder outlet obstruction
• Perform physical examination in patients diagnosed as BOO in pressure-flow study by urethral evaluation with 16 Fr urethral sound: if there is resistance to 16Fr sound, it will be diagnosed as anatomical BOO and the patients can not participate in the study.
• Previous surgical procedures related to incontinence or cystocele
• Pregnant or nursing women
• Intake of medications and drugs affecting bladder function: alpha blocker, anticholinergic
• Anticholinergic drugs: Tolterodine, Oxybutynin, Propiverin, Trospium, Solifenacin, SSRI including TCA
• Cholinergic drug: Bethanechol
• Any other blocker other than alfuzosin
• patients can be enrolled after wash-out
• Any positive urine culture had to be successfully treated before the recruitment.
• Clinically significant ( ≥ Stamey grade II/III) stress incontinence as determined by the investigator and confirmed for female patients by a cough provocation test.
• Recurrent UTIs defined as having been treated for symptomatic UTIs ≥ 4 times in the last year
• Diagnosed or suspected interstitial cystitis
• Patients with marked cystocele or other clinically significant pelvic prolapse.
• Treatment within the 14 days preceding randomization, or expected to initiate treatment during the study with:
• Estrogen treatment started more than 2 months prior to inclusion will be allowed
• Receipt of any electrostimulation or bladder training within the 14 days before randomization, or expected to start such treatment during the study.
• Hypersensitive to the study drug
• Orthotopic hypotension or history of orthotopic hypotension
• Intake of calcium channel blockers
• Severe hepatic or renal dysfunctions

• Handok Pharmaceuticals Co., Ltd.
• The Korean Urological Association